Association of Coffee Consumption and Prediagnostic Caffeine Metabolites with Incident Parkinson Disease in a Population-Based Cohort
Neurol 102:e209201, Zhao,Y.,et al, 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
The Neuroprotective Effects of Caffeine: A Prospective Population Study (the Three City Study)
Neurol 69:536-545, Ritchie,K.,et al, 2007
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
JAMA 296:2832-2838, Munger,K.L.,et al, 2006
Calcium Antagnosits in Aneurysmal Subarachnoid Hemorrhage
Stroke 36:1816-1817, Rinkel,G.J.E.,et al, 2005
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Arch Neurol 60:203-208, Luchsinger,J.A.,et al, 2003
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Arch Neurol 60:1059-1064,1043, Chen,H.,et al, 2003
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Estrogen-replacement Therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging
Neurol 50:996-1002, Baldereschi,M.,et al, 1998
Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997
Risk of Alzheimer's Disease and Duration of NSAID Use
Neurol 48:626-632, Stewart,W.F.,et al, 1997
A Prospective Study of Estrogen Replacement Therapy and the Risk of Developing Alzheimer's Disease
Neurol 48:1517-1521, Kawas,C.,et al, 1997
Dietary Antioxidants and Parkinson Disease
Arch Neurol 54:762-765, deRijk,M.C.,et al, 1997
The Relation Between Fish Consump & Stroke Incidence, NHANES I Epidemiol Study
Arch Int Med 156:537-542, Gillum,R.F.,et al, 1996
Cognitive Impairment & Mortality in a Cohort of Elderly People
BMJ 312:608-611, Gale,C.R.,et al, 1996
Dietary Flavonoids, Antioxidant Vitamins, and Incidence of Stroke
Arch Int Med 154:637-642, Keli,S.O.,et al, 1996
Arthritis & Anti-Inflammatory Agents as Possible Protective Factors for Alzheimer's Dis:Review of 17 Epidemiologic Studies
Neurol 47:425-432, McGeer,P.L.,et al, 1996
Routine Indomethacin Prophylaxis:Has the Time Come
Pediatrics 98:784-785, Bada,H.S., 1996
Cigarette Smoking and Protection from Parkinson's Disease:False Association or Etiologic Clue?
Neurol 45:1041-1051, Morens,D.M.,et al, 1995
Head Injury
JNNP 58:526-539, Teasdale,G.M., 1995
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Prophylactic Neuroprotection for Cerebral Ischemia
Stroke 25:1075-1080, Fisher,M.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation
NEJM 392:2403-2412, 2473, Kharbanda,R.K.,et al, 2025
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Treatment and Outcomes of Cervical Artery Dissection in Adults:A Scientific Statement From the American Heart Association
Stroke 55:e91-e106, YaghikS.,et al, 2024
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Congenital Cytomegalovirus Infection
BMJ 373:m1212, Pesch, M.H.,et al, 2021
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Cholesterol Lowering and Prevention of Stroke
Stroke 50:537-541, Hackam, D.G. & Hegele, R.A., 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Increasing Prevalence of Vascular Risk Factors in Patients with Stroke
Neurol 89:1985-1994, Otite, F.O.,et al, 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016
Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis
JAMA 316:592-601,587, Haussig, S.,et al, 2016